- Home
- IFRX vs RDIB Comparison
IFRX vs RDIB Comparison
Compare IFRX & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- RDIB
- Stock Information
- Founded
- IFRX 2007
- RDIB 1937
- Country
- IFRX Germany
- RDIB United States
- Employees
- IFRX N/A
- RDIB N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- RDIB Movies/Entertainment
- Sector
- IFRX Health Care
- RDIB Consumer Discretionary
- Exchange
- IFRX Nasdaq
- RDIB Nasdaq
- Market Cap
- IFRX 117.8M
- RDIB 140.2M
- IPO Year
- IFRX 2017
- RDIB N/A
- Fundamental
- Price
- IFRX $1.00
- RDIB $7.50
- Analyst Decision
- IFRX Strong Buy
- RDIB
- Analyst Count
- IFRX 2
- RDIB 0
- Target Price
- IFRX $9.00
- RDIB N/A
- AVG Volume (30 Days)
- IFRX 322.6K
- RDIB 11.8K
- Earning Date
- IFRX 05-07-2025
- RDIB 05-14-2025
- Dividend Yield
- IFRX N/A
- RDIB N/A
- EPS Growth
- IFRX N/A
- RDIB N/A
- EPS
- IFRX N/A
- RDIB N/A
- Revenue
- IFRX $171,642.00
- RDIB $210,527,000.00
- Revenue This Year
- IFRX $106.72
- RDIB N/A
- Revenue Next Year
- IFRX $66.89
- RDIB $18.29
- P/E Ratio
- IFRX N/A
- RDIB N/A
- Revenue Growth
- IFRX 162.79
- RDIB N/A
- 52 Week Low
- IFRX $1.01
- RDIB $5.78
- 52 Week High
- IFRX $2.82
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- IFRX 33.87
- RDIB 50.66
- Support Level
- IFRX $1.01
- RDIB $6.70
- Resistance Level
- IFRX $1.18
- RDIB $8.65
- Average True Range (ATR)
- IFRX 0.12
- RDIB 0.95
- MACD
- IFRX 0.01
- RDIB -0.08
- Stochastic Oscillator
- IFRX 3.66
- RDIB 14.29
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.